Vitality Biopharma Inc (OTCMKTS:VBIO) continues to be a undervalued stock in the buzzing cannabis industry. It intends to target NBS and IBD. Beginning in 2014, pot stocks were in vogue. Shareholders were scrambling the industry to list almost any firm that promoted as an emerging entity in the cannabis market.
The disadvantage in that investment plan, however, was that many shareholders were too preoccupied with listing a firm with a catchy title, rather than a firm that really had some substance. While shareholders were drawn in by the illusion that millions would be fetched by investing in the firms that purportedly intended to cultivate and sell leisure and medical based pot, they should have been concentrated on investing in firms that are intent on using the crop’s cannabinoid properties, which are steadily demonstrating extraordinary advantage in curing a host of medical ailments.
With that said, if shareholders had only remained attentive on seeking lucrative and realistic potential via cannabis pharmaceuticals, Vitality Biopharma would not have been disregarded. In fact, it is one of only 3 cannabinoid related firms that they witness as actually being able to manufacture any significant revenue in the imminent few years.
The so termed “green rush” that started in 2014 led shareholders to a host of penny shares names, many of whom misguided shareholders with pipe dreams of getting a position in the growing multi-billion-dollar pot industry that has advanced through the relaxation of pot laws throughout the U.S. and abroad.
While many of these stock lottery tickets were coming out from press releases boasting on the prospects in their future, just three stocks were really working on measures that can direct to actual long-term shareholder value and a leading market position in both the short and long term. VBIO is one of a few Hemp drug firms that can point towards significant clinical data that displays cannabis has been beneficial for its main drug indication, IBD.